Compare · ABBV vs ATAI
ABBV vs ATAI
Side-by-side comparison of AbbVie Inc. (ABBV) and AtaiBeckley Inc. (ATAI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and ATAI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV carries a market cap of $521.50B.
- Over the past year, ABBV is up 26.2% and ATAI is up 85.6% - ATAI leads by 59.5 points.
- ABBV has hit the wire 15 times in the past 4 weeks while ATAI has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- AbbVie Inc.
- AtaiBeckley Inc.
- Price
- -
- -
- Market cap
- $521.50B
- -
- 1M return
- +4.12%
- +1.73%
- 1Y return
- +26.15%
- +85.61%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2008
- News (4w)
- 15
- 0
- Recent ratings
- 25
- 25
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
AtaiBeckley Inc.
Atai Life Sciences N.V. focuses on operating as a holding company for ATAI Life Sciences AG that operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01 is a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Latest ABBV
- EVP, CHIEF COMMERCIAL OFFICER Stewart Jeffrey Ryan exercised 40,619 shares at a strike of $101.75, sold $11,925,738 worth of shares (40,619 units at $293.60) and gifted 3,450 shares, decreasing direct ownership by 4% to 79,721 units (SEC Form 4)
- Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications
- SEC Form 10-Q filed by AbbVie Inc.
- Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026
- AbbVie Inc. filed SEC Form 8-K: Leadership Update
- Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Reports Third-Quarter 2026 Financial Results
- AbbVie TEMPLE Study Demonstrates Superior Tolerability and Efficacy of Atogepant (QULIPTA®) in Head-to-Head Migraine Prevention Trial
- The Countdown Is On: BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18
Latest ATAI
- SEC Form 15-12G filed by AtaiBeckley Inc.
- SEC Form S-8 POS filed by AtaiBeckley Inc.
- SEC Form S-8 POS filed by AtaiBeckley Inc.
- SEC Form S-8 POS filed by AtaiBeckley Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by AtaiBeckley Inc.
- Chief Medical Officer Craig Kevin James returned 8,437 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax
- SEC Form 4 filed by Chief Operating Officer Kochendoerfer Gerd (for withholding tax)
- Officer Barrett Christopher Ryan Cave returned 155,066 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding tax)
- Chief Scientific Officer Short Glenn Frank returned 42,333 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Hoffman John Francis to satisfy tax liability